| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7105530 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Oct, 2023
(24 days from now) | |
Votrient is owned by Novartis.
Votrient contains Pazopanib Hydrochloride.
Votrient has a total of 1 drug patent out of which 0 drug patents have expired.
Votrient was authorised for market use on 19 October, 2009.
Votrient is available in tablet;oral dosage forms.
The generics of Votrient are possible to be released after 19 October, 2023.
Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2009
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
VOTRIENT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic